ESAB's Dividend Raise Is a Confidence Signal, Not an Income Story

On September 10, ESAB Corporation's board declared a quarterly dividend of $0.12 a share, payable in October. On its face that is an increase — up from the $0.10 the welding and cutting equipment maker paid through most of the past year. But on a stock that has fallen from about $137 in February to roughly $69 today, four $0.12 payments come to less than a 0.7% yield. The dividend headline is almost beside the point: the real matter is how a self-described "premier industrial compounder" lost half its market value, and whether what replaced that value — debt — changes what the stock is for.

The compounding was bought, not built

ESAB, spun out of Colfax in 2022, makes welding and cutting equipment, consumables, and gas control gear. For most of its short public life the market treated it as a steadily compounding industrial, and the shares peaked near $137 in early 2026. Then the story turned. The stock is down roughly 38% year to date and about half from that high. The proximate cause is not a collapsed end market; it is a string of acquisitions capped by Eddyfi, a non-destructive testing business bought for $1.45 billion and closed in January, a full year ahead of the original schedule.

The top line still grows, but increasingly the growth is purchased rather than produced. In the first quarter, record total sales rose 10% while core organic sales — the number that strips out acquisitions and currency — fell 1%. The second quarter was better: total sales up 12.9%, but core organic up just 2.5%. Management's own 2026 guidance draws the same line: total sales growth of 11% to 14%, with only 2% to 4% organic and roughly 9 points contributed by mergers. An investor reading that has to notice the compounder's realized growth rate is now a low-single-digit organic number with an acquisition program bolted on top.

How the growth was financed

That is where the balance sheet becomes the first equity test. Eddyfi was funded with a $1 billion private placement of 5.625% senior notes due 2031—about $56 million of interest a year on that tranche alone—plus $175 million of Series A mandatory convertible preferred stock carrying a 6.5% cumulative dividend. Cash and debt left net debt near $2.2 billion against guided EBITDA of roughly $615 to $625 million, or something like 3.5 times. Management says it is focused on "deleveraging the business."

The cost is already showing up in reported results. Second-quarter net income fell to $35 million, $0.54 a diluted share, hit by acquisition and restructuring charges and higher financing costs, while adjusted EPS of $1.33 missed the street's $1.43. Full-year adjusted EPS guidance was trimmed to $5.40 to $5.50. The multiple compression is not fear without a basis: the market repriced a compounder as a leveraged serial acquirer whose near-term earnings are being diluted by the very spending meant to preserve growth.

What the dividend tells you

The good news buried in the announcement is that the payout is not at risk. Common dividends run to roughly $30 million a year against free cash flow over the past year of about $200 million — a payout ratio in the high teens. The board could have raised the dividend several times over and still not strained a quarter's cash flow. That is why the 20% bump reads as a confidence signal, sent even as management borrows to grow and promises to pay the debt down, rather than as an income event. A company that pays out under 1% of its market capitalization in dividends is not paying you to own it; it is telling you it can afford to.

What this means for the risk-reward

At roughly $69, ESAB trades in the low-to-mid teens on forward adjusted earnings and near 10 times forward EBITDA after the correction itself has removed the speculative premium. That is not obviously a bargain. The halving registered real deterioration — leverage, bought growth, and an EPS-miss quarter — and the earnings base carrying that multiple still owes about $2.2 billion that the market ranks ahead of shareholders.

The value question turns on one gate: whether free cash flow can service the interest, keep the dividend, and make a real dent in that debt while organic growth runs 2% to 4%. With about $200 million of annual free cash flow against $2.2 billion of net debt, deleveraging is a years-long arithmetic unless management sells assets or the equity absorbs further dilution from the mandatory preferred. For an income investor this is not an anchor — the yield is too small to matter. For a value investor it is a watchlist name, not yet a conviction: the cheapness is real only if Eddyfi's contribution compounds faster than the interest that paid for it. The dividend raise is a small positive, but the number worth sacrificing the headline for is the net-debt balance, not the $0.12.